UCB stock loses 0.61 percent pre-market to EUR 202.30
Published on 10/08/2026 at 08:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB stock was at EUR 202.30 pre-market at 8:26 a.m. CEST on October 8, 2026, down 0.61 percent versus the EUR 203.55 prior close at Lang & Schwarz on October 7, 2026. The quote was recorded before the Xetra session began.
Pre-market indication
Lang & Schwarz showed a bid of EUR 201.60 and an ask of EUR 203.00 alongside the pre-market price. The figures describe the euro indication for investors in Germany and do not include a primary-exchange price in another currency. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of UCB stock.
Earlier medical update
In a release dated September 29, UCB said it would present data from its generalized myasthenia gravis portfolio at the 2026 AANEM Congress Annual Meeting and the Myasthenia Gravis Foundation of America Scientific Session, held from September 29 through October 2 in Orlando, Florida. The company highlighted analyses involving ZILBRYSQ and RYSTIGGO, patient perspectives on ocular myasthenia gravis, and interim Phase 1b data for the investigational BCMA×CD3 T-cell engager cizutamig. The release said UCB would also host an industry therapeutic update and presentation sessions. PR Newswire distributed the announcement.
